Piribo: New publication announcement, Global Generics Guide: Part 2

The generics market is undergoing significant change, with intense merger and acquisition activity, a raft of upcoming patent expiries and new legislation being enacted to promote generic prescription in the major markets. In addition, key issues, such as authorized generics, the first biosimilars approvals and increasing competition within the market are also affecting growth dynamics

Highlights
There is still room for growth in the more mature generics markets, with governments examining methods of increasing generic usage even further. However, pricing pressures may result in this growth not being translated into positive returns for the generics industry.Competition in the generics market is becoming increasingly intense, with low cost producers expanding globally and branded Pharma becoming involved through subsidiaries or via authorized generic agreements. The wave of consolidation that swept through the generics market has been spurred on by this competition and is unlikely to end any time soon.The biosimilars market has moved on in 2006, with two products (Sandoz's Omnitrope and Biopartners' Valtropin) being approved in the EU. Omnitrope was finally approved in the US, after a lengthy delay, but the FDA has stated that this does not set a precedent for future approvals of other biosimilars.

Scope
- Overview of the size of the generics market in the US, Japan, France, Germany, Italy, Spain and the UK
- Assessment of the various policies being implemented to promote generic prescribing and drug use
- Analysis of key strategic issues including M&A, authorized generics and patent challenges
- Examination of the future areas for generic growth, including an update of the biosimilars situation
Reasons to Purchase
- Identify the key factors and issues that will either promote or prevent generic growth in each of the seven major markets
- Understand the changing competitive dynamics within the generics industry and plan your own strategies accordingly
- Assess the strategic issues that are affecting the generics industry and how the key players are addressing them

Contents
Chapter 1 Executive Summary
Chapter 2 Generics Market Dynamics
Chapter 3 Strategies For Success: Growth Through Co-Operation
Chapter 4 Strategies For Success: Patent Challenges
Chapter 5 Future Outlook

“Global Generics Guide: Part 2 - Benchmarking country markets and strategic issue” is available from Piribo. For more information go to: http://www.piribo.com/publications/generic_drugs/global_generics_guide_part.html

Piribo Product ID: DAT522

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.